4 results
The primary objective is:* To evaluate RBC transfusion independence (RBC-TI) of luspatercept compared with placebo for the treatment of anemia due to IPSS-R very low, low, or intermediate risk MDS in subjects with ring sideroblasts (* 15%) who…
Primary Safety Objective: • To evaluate initial safety of UCon for treatment of OAB symptoms in a home setting.Secondary Safety Objective• To demonstrate that subjects using UCon do not experience an unacceptable amount of device- or procedure…
Primary objective:• To evaluate the efficacy of luspatercept on RBC transfusion independence (RBC-TI for 12 weeks [84 days] with an associated concurrent mean hemoglobin increase >= 1.5 g/dL) compared with epoetin alfa for the treatment of…
We will investigate how safe the study device DV3395-C1 is when it is taken in by healthy participants. We will also look at the passage (i.e., gastrointestinal transit time) and activation of the study device. For this, we will see if the device…